发布求助
文献互助 智能选刊 最新文献

Skinmed最新文献

筛选
英文 中文
Lichen Sclerosus in Perspective. 透视硬皮病。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Alison Romisher, Casey L Ross, Nicholas A Ross
{"title":"Lichen Sclerosus in Perspective.","authors":"Alison Romisher, Casey L Ross, Nicholas A Ross","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Lichen sclerosus (LS) was first described in women by a researcher in 1887.<sup>1</sup> It was recognized in men by another investigator in 1928.<sup>2</sup> Lichen sclerosus is a chronic, inflammatory lymphocytic dermatosis that occurs in anywhere from 1:30 to 1:1,000 adults.<sup>3,4</sup> There is a slight predominance of women, with a bimodal age distribution in pre-pubertal individuals and again in life's sixth-seventh decades. Studies have established that the majority with pre-pubertal onset continue to have adulthood disease.<sup>5</sup> Psychosocial implications of this disease, specifically self-image, anxiety, and sexual function, can be debilitating for patients.<sup>6-9</sup> As no cure has been described for lichen sclerosus. Treatment is aimed at symptomatic relief and preventing additional effacement. Unfortunately, the scarring that occurs is usually permanent.<sup>10,11</sup> As it is unclear whether treatment alters the theoretic risk of malignant degeneration, estimated at 4%-5%,<sup>12,13</sup> frequent clinical examinations are indicated.<sup>14-17</sup>.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Juvenile Dermatomyositis: Diagnosis and Management. 幼年皮肌炎：诊断与管理。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Amina Aounallah, Sarra Saad, Nadia Ghariani Fetoui, Mohamed Denguezli
{"title":"Juvenile Dermatomyositis: Diagnosis and Management.","authors":"Amina Aounallah, Sarra Saad, Nadia Ghariani Fetoui, Mohamed Denguezli","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Juvenile dermatomyositis (JDM) is the leading cause of chronic idiopathic inflammatory myopathy of auto-immune origin in children. Seven patients with JDM found in the records from 1998-2019 of the Department of Dermatology Farhat Hached Hospital, Sousse, Tunisia. Our study concerned a total of six girls and one boy with a median age at disease onset of 8,16 years. The average time before diagnosis was 8,8 months. The onset of the disease was acute in 2 patients. All patients displayed skin manifestations at diagnosis, with proximal muscular weakness in 4 cases. Four patients had elevated muscle enzymes and all of them showed myopathic findings on electromyography. Oral corticosteroids were prescribed in 6 patients, in association with other systemic therapies. Three patients achieved a good outcome while two others relapsed. The two other patients showed corticosteroids resistance with a fatal outcome in one case. This study highlights the diagnostic features and management of juvenile dermatomyositis.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DAXXIFYTM (DaxibotulinumtoxinA-Lanm) for Injection, for Intramuscular Use. 注射用 DAXXIFYTM（DaxibotulinumtoxinA-Lanm），用于肌肉注射。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Aditya K Gupta, Avantika Mann, Kimberly Vincent, William Abramovits
{"title":"DAXXIFY<sup>TM</sup> (DaxibotulinumtoxinA-Lanm) for Injection, for Intramuscular Use.","authors":"Aditya K Gupta, Avantika Mann, Kimberly Vincent, William Abramovits","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>DAXXIFY<sup>TM</sup> (daxibotulinumtoxinA-lanm) for intramuscular injection was recently approved for temporary improvement in the appearance of the moderate to severe glabellar lines (GLs) associated with corrugator and/or procerus muscle activity in adult patients. DaxibotulinumtoxinA for Injection (DAXI) includes a purified 150-kDA botulinum toxin Type A (BoNTA) formulated with a novel peptide excipient that is positively charged and helps to bind the neurotoxin to negatively charged neuronal membrane for a longer duration. The effectiveness of DAXI was evaluated in two phase 3 trials, SAKURA 1 and SAKURA 2, using a randomized, double-blind, placebo-controlled design. The primary endpoint (treatment success) was a composite clinical outcome (investigator and subjects) of ≥2-point improvement in severity of GLs at week 4. In SAKURA 1, the treatment success was 74% (148/201) in subjects treated with DAXI and 0% in subjects treated with placebo. In SAKURA 2, the treatment success was 74% (152/205) in subjects treated with DAXI and 0% in subjects treated with placebo. An open-label study, SAKURA 3, included 2,691 participants, who underwent three consecutive treatment cycles. These individuals were recruited from either SAKURA 1 or SAKURA 2 trials, or were new to the study and received DAXI. Treatment success proportions were 73.2%, 77.7%, and 79.6% across the three consecutive treatment cycles. The recommended dose is 40 units for the Glabellar-complex divided in traditional five intramuscular injections at five injection sites (medial and lateral corrugator bilaterally and one injection in the procerus muscle).</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Monkeypox (Mpox) Dilemmas: What Is the Clinical and Histologic Presentation of the Bullae and Are They Infectious, and Why Is the Infection Dying Out So Quickly? 猴痘（Mpox）难题：囊泡的临床和组织学表现是什么，是否具有传染性，为什么感染很快就消失了？
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
W Clark Lambert, Michael Lavery, Muriel Lambert, Albert Alhatem, Robert A Schwartz, Rohan Shah, Claude E Gagna
{"title":"The Monkeypox (Mpox) Dilemmas: What Is the Clinical and Histologic Presentation of the Bullae and Are They Infectious, and Why Is the Infection Dying Out So Quickly?","authors":"W Clark Lambert, Michael Lavery, Muriel Lambert, Albert Alhatem, Robert A Schwartz, Rohan Shah, Claude E Gagna","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Childhood Acral Acanthosis Associated with Obesity. 与肥胖有关的儿童痤疮。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Avita Dhiman, Manmohan Bagri, Neirita Hazarika
{"title":"Childhood Acral Acanthosis Associated with Obesity.","authors":"Avita Dhiman, Manmohan Bagri, Neirita Hazarika","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dermatology One Hundred Years Ago. 百年前的皮肤病学
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Lawrence Charles Parish, W Clark Lambert
{"title":"Dermatology One Hundred Years Ago.","authors":"Lawrence Charles Parish, W Clark Lambert","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cannabidiol in Dermatology: Proposed Mechanism of Action and Potential Medication Interactions. 皮肤病学中的大麻二酚：拟议的作用机制和潜在的药物相互作用。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Brittany M Snyder, Shannon C Trotter
{"title":"Cannabidiol in Dermatology: Proposed Mechanism of Action and Potential Medication Interactions.","authors":"Brittany M Snyder, Shannon C Trotter","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In the setting of increasing patient-reported cannabidiol (CBD) usage in the dermatologic setting, it is of great importance that clinicians become aware of potential medication interactions that may arise from cannabidiol usage in order to ensure safe and efficacious medication therapy. This brief review aimed to bring awareness to the mechanism of CBD while highlighting potential interactions between CBD and medication therapy for commonly encountered dermatologic conditions, including acne, allergic contact dermatitis, atopic dermatitis, pruritus, skin aging, skin cancer, and psoriasis.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Well-Demarcated Acral Scaly Pigmented Eruption. 界限分明的鳞状色素性溃疡
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Anissa Zaouak, Oumayma Magdoud, Raja Jouini, Houda Hammami, Samy Fenniche
{"title":"A Well-Demarcated Acral Scaly Pigmented Eruption.","authors":"Anissa Zaouak, Oumayma Magdoud, Raja Jouini, Houda Hammami, Samy Fenniche","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OpzeluraTM (Ruxolitinib) Cream 1.5. OpzeluraTM (Ruxolitinib) 乳霜 1.5。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
William Abramovits, Akhil Abraham, Kimberly Dawn Vincent, Aditya K Gupta
{"title":"Opzelura<sup>TM</sup> (Ruxolitinib) Cream 1.5.","authors":"William Abramovits, Akhil Abraham, Kimberly Dawn Vincent, Aditya K Gupta","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Ruxolitinib cream 1.5% was first approved by the US Food and Drug Administration (FDA) in 2011. Opzelura™ cream was introduced by Incyte Dermatology in 2021 for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients aged ≥12 years, whose clinical manifestations are not controlled with prescribed topical therapies, such as topical corticosteroids, topical calcineurin inhibitors, or topical phosphodiesterase-4 ( PDE4) inhibitors, or when such therapies are not advisable. Ruxolitinib is a Janus kinase (JAK) inhibitor that addresses inflammation in AD. It selectively inhibits JAK1 and JAK2, blocking JAK and activating signal transducer and activator of transcription (STAT), thereby interrupting the cytokine pathways responsible for cutaneous inflammation. The targeted downstream cytokines include Interleukin- 4 (IL-4), IL-13, IL-31, and cytokine thymic stromal lymphopoietin (TSLP), which play pivotal roles in the itching and inflammation experienced by AD patients. Ruxolitinib cream is directly applied as a thin layer over AD lesions twice daily up to 20% body surface area (BSA) using no more than 60 g per week. It can be used for up to 8 weeks on delicate or thin skin surfaces.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two Features of Annular Lichenoid Dermatitis of Youth (ALDY). 青年环状苔癣性皮炎（ALDY）的两个特征。
Skinmed Pub Date : 2024-09-17 eCollection Date: 2024-01-01
Elie Saliba, Amal Alawami, Ahmad Berjawi, Sara Yumeen, Zeina Tannous
{"title":"Two Features of Annular Lichenoid Dermatitis of Youth (ALDY).","authors":"Elie Saliba, Amal Alawami, Ahmad Berjawi, Sara Yumeen, Zeina Tannous","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A healthy 14-year-old boy presented with a 2-month history of two slowly expanding asymptomatic lesions on his right trunk. No etymology of any new medications, recent travel, or tick bites was reported. Physical examination demonstrated two 4.5×2.5- cm and 3.5×2-cm annular hyperpigmented plaques with slightly elicited red borders on the right lower abdomen and right inferior flank. No evidence of atrophy or sclerosis was noted (Figure 1A). A 4-mm punch biopsy revealed irregular epidermal hyperplasia with alteration of thinned and quadrangular rete ridges, a dense band-like lichenoid infiltrate in the papillary dermis admixed with numerous melanophages and occasional necrotic keratinocytes. No evidence of epidermotropism was observed (Figure 1B). The dermal infiltrate was predominantly composed of CD3+ T-lymphocytes admixed with rare CD20+ B-lymphocytes and increased CD8-CD4 ratio. The patient showed significant improvement following the application of a potent steroid ointment for several weeks.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信